Skip to Main Content

A version of this story first appeared in STAT’s free biotech newsletter, The Readout. Sign up here to subscribe.

Sometimes, the market delivers tidy reminders that biotech companies are often at the whim of things they cannot control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!